1. Introduction {#s0005}
===============

The pyrazole moiety is a versatile lead molecule in the pharmaceutical development and has a wide range of biological activities ([@b0045]; [@b0025]; [@b0065]), antibacterial ([@b0105]), antifungal ([@b0050], [@b0005]) and pharmacological activities such as anti-inflammatory ([@b0060]), antitubercular ([@b0020]), anticancer ([@b0070]), analgesic ([@b0110]), antipyretic ([@b0030]), anticonvulsant ([@b0010]) activities.

Commercially available pyrazole moiety ([Fig. 1](#f0005){ref-type="fig"}) such as Celecoxib is potent COX-2 inhibitor ([@b0075]). Some other examples of pyrazole derivatives as NSAID are ramifenazone ([@b0040]), Lonazolac (NSAID) ([@b0090]) and Rimonabant ([@b0055]). Compound (phenylbutazone) is a non steroidal drug ([@b0085], [@b0115]). Pyrazofurin is potential of antiviral activity, HCV virus ([@b0100], [@b0095], [@b0080], [@b0035]). In the current research, anti-inflammatory drug has been used in most prominent research areas. New anti-inflammatory drugs were previously used in clinical research, some of the drugs are still not efficient and have intolerable side effects.

Based on the above study, we need to develop new drugs against anti-inflammatory and antimicrobial activities. Therefore, we were led to identify new approaches of pyrazole derivatives as well as test the antimicrobial and anti-inflammatory activity.

2. Methods and materials {#s0010}
========================

2.1. Chemicals and reagents {#s0015}
---------------------------

All chemicals were acquired from Sigma--Aldrich Chemical Co (Sigma--Aldrich Corp., St. Louis, MO, USA). The Infrared spectra (KBr), Proton NMR, Carbon NMR, Mass spectra (EI), and Elemental analysis (C, H, N and S) were recorded using Shimadzu 8201PC (4000--400 cm^−1^), Bruker DRX-400 MHz, Jeol JMS D-300 spectrometer operating, and Elementer analyser model (Varian EL III).

### 2.1.1. Synthesis of 2-((5-hydroxy-3-methyl-1*H*-pyrazol-4-yl)(phenyl)methyl)hydrazinecarboxamide (1) {#s0020}

A mixture of 5-hydroxy-3-methyl-1*H*-pyrazoles (0.1 mol), benzaldehyde (0.1 mol) and semicarbazide hydrochloride (0.1 mol) was treated with ultrasound irradiation under ethanol medium. After completion of reaction, the product was isolated and identified by TLC. The identified product was separated from column chromatography and recrystallized by suitable solvent. The above experiential procedure was pursued by remaining compounds **2**--**6**.

IR (cm^−1^): 3445 (C--OH), 670(--CH--), 1679 (NH CO), 1569 (NH~2~). ^1^H NMR (DMSO-d~6~): δ 9.90 (s, 1H, C--OH), 2.71 (d, *J *= 4.4 Hz, 1H, CH), 2.23(s, 3H,CH~3~), 4.45 (dd, *J *= 5.3 Hz, 1H, --CH--), 7.33--7.49 (m, 5H, Phenyl ring), 2.36 (d, *J *= 2.0 Hz, 1H, NH), 6.81 (d, *J *= 1.4 Hz, 1H, NH), 6.25 (s, 2H, NH~2~). ^13^C NMR (CDCl~3~): δ 167.2(C--OH), 162.6 (C--CH~3~), 42.2(C--CH--), 52.3(C--CH--NH), 18.7(C--CH~3~), 155.4(CONH~2~), 141.7, 112.0, 129.2, 133.8 (Phenyl ring). Mass (m/z): 261.27 (M^+^, 32%), 244.28, 216.38, 200.27 (100%), 185.26, 170.25, 94.15.

### 2.1.2. 2-\[(4-chlorophenyl)(3-hydroxy-5-methyl-4H-pyrazol-4-yl)methyl\]hydrazinecarboxamide(2) {#s0025}

IR (cm^−1^): 3469 (C--OH), 691(--CH--), 1665 (NH CO), 1554(NH~2~), 897(C--Cl). ^1^H NMR (DMSO-d~6~): δ 9.96(s, 1H, C--OH), 2.76 (d, *J *= 4.3 Hz, 1H, CH), 2.29 (s, 3H, CH~3~), 4.30(dd, *J *= 5.2 Hz, 1H, --CH--), 7.21--7.39 (dd, 4H, Phenyl ring), 2.31 (s, *J *= 2.1 Hz, 1H, NH), 6.73 (s, *J *= 1.6 Hz, 1H, NH), 6.19 (s, 2H, NH~2~). ^13^C NMR (CDCl~3~): δ 167.2 (C--OH), 162.6 (C--CH~3~), 42.2 (C--CH--), 52.3 (C--CH--NH), 18.7 (C--CH~3~), 155.4 (CONH~2~), 141.7, 112.0, 129.2, 133.8 (Phenyl ring). Mass (m/z): 295.72(M^+^, 26%), 277.74, 243.30 (100%), 228.28, 200.27, 185.26, 170.25, 94.15.

### 2.1.3. 2-((3-hydroxy-5-methyl-4H-pyrazol-4-yl)(4-hydroxyphenyl)methyl)hydrazinecarboxamide (3) {#s0030}

IR(cm^−1^): 3457(C--OH), 682(--CH--), 1661(NHCO), 1508(NH~2~), 1447(OH).^1^H NMR(DMSO-d~6~): δ 9.89 (s, 1H, C--OH), 2.70(d, *J *= 4.1 Hz, 1H,CH), 2.31 (s, 3H, CH~3~), 4.36(dd, *J *= 5.6 Hz, 1H, --CH--), 7.23--7.31 (dd, 4H, Phenyl ring), 2.33 (s, *J *= 2.3 Hz, 1H, NH), 6.70 (s, *J *= 1.6 Hz, 1H, NH), 6.21 (s, 2H, NH~2~). ^13^C NMR (CDCl~3~): δ 167.9 (COH), 163.2 (C2--CH~3~), 42.6 (C--CH--), 51.9 (C--CH--NH), 18.5 (C--CH~3~), 155.0 (CONH~2~), 146.7, 111.5, 128.2, 137.2 (Phenyl ring). Mass (m/z): 277.27(M^+^, 22%), 259.30, 243.42(100%), 228.28, 200.27, 185.26, 170.25.

### 2.1.4. 2-\[(3-hydroxy-5-methyl-4H-pyrazol-4-yl)(4-nitrophenyl)methyl\]hydrazinecarboxamide (4) {#s0035}

IR(cm^−1^); 3450 (C--OH), 679(--CH--), 1660 (NHCO), 1514(NH~2~), 1536(C--NO~2~). ^1^H NMR (DMSO-d~6~): δ9.91 (s, 1H, C--OH), 2.79(d, *J *= 4.6 Hz, 1H, CH), 2.32 (s, 3H, CH~3~), 4.41 (dd, *J *= 5.2 Hz, 1H, --CH--), 7.29--7.42 (dd, 4H, Phenyl ring), 2.39 (d, *J *= 2.1 Hz, 1H, NH), 6.81 (d, *J *= 1.7 Hz, 1H, NH), 6.26 (s, 2H, NH~2~). ^13^C NMR (CDCl~3~): δ167.1(C--OH), 162.9(C--CH~3~), 42.0 (C--CH--), 52.6 (C--CH--NH), 19.8 (C--CH~3~), 156.3 (CONH~2~), 142.9, 112.5, 128.2, 131.2 (Phenyl ring). Mass (m/z): 306.27(M^+^, 26%), 289.28, 261.27, 245.27(100%), 200.27, 185.26, 170.25.

### 2.1.5. 2-\[(3-hydroxy-5-methyl-4H-pyrazol-4-yl)(4-methoxy phenyl)methyl\]hydrazine carboxamide(5) {#s0040}

IR (cm^−1^): 3460 (C--OH), 682(--CH--), 1668 (NHCO),1508 (NH~2~).^1^H NMR (DMSO-d~6~): δ 9.92 (s, 1H, C--OH), 2.76 (d, *J *= 4.1 Hz, 1H, CH),2.36 (s, 3H, CH~3~),4.28 (dd, *J *= 5.5 Hz, 1H, --CH--),7.19--7.25 (dd, 4H, Phenyl ring), 2.39 (d, *J *= 2.2 Hz, 1H, NH), 6.84(d, *J *= 1.5 Hz,1H, NH), 6.15(s,2H, NH~2~).^13^C NMR (CDCl~3~): δ 167.3 (C--OH), 162.0 (C--CH~3~), 42.9 (C--CH--), 53.1 (C--CH--NH), 19.1 (C--CH~3~), 156.8 (CONH~2~),141.7,112.0,129.2, 133.8 (Phenyl ring). Mass (1 *m*/*z*): 291.30(M^+^, 41%), 259.30, 243.30, 200.27(100%), 185.26, 170.25, 94.15.

### 2.1.6. 2-((4-(dimethylamino)phenyl)(3-hydroxy-5-methyl-4H-pyrazol-4-yl)methyl)hydrazinecarboxamide (6) {#s0045}

IR (cm^−1^): 3451 (C--OH), 663(--CH--), 1679 (NHCO), 1512 (NH~2~). ^1^H NMR (DMSO-d~6~): δ 9.95 (s, 1H, C--OH), 2.76 (d, *J *= 4.3 Hz, 1H, CH), 2.24 (s, 3H, CH~3~), 4.41(dd, *J *= 5.6 Hz, 1H, --CH--),7.29--7.41 (dd, 4H, Phenyl ring), 2.36 (d, *J *= 2.3 Hz, 1H, NH), 6.82(d, *J *= 1.9 Hz, 1H, NH), 6.17 (s, 2H, NH~2~). ^13^C NMR (CDCl~3~): δ167.9 (C--OH), 162.5(C--CH~3~), 43.1(C--CH--), 54.6 (C--CH--NH), 18.9(C--CH~3~), 157.1 (CONH~2~), 142.8, 113.0, 127.2, 134.1 (Phenyl ring). Mass (*m*/*z*): 304.34 (M^+^, 27%), 286.37, 276.30, 243.34(100%), 200.27, 185.26, 170.25, 94.15.

2.2. Pharmacological activity {#s0050}
-----------------------------

### 2.2.1. Anti-inflammatory activity {#s0055}

Isolated compounds (**1**--**6**) were evaluated by anti-inflammatory activity, screening method followed from the literature method ([@b0125]). Albino rats of both sexes weighing 150 g were divided into 4 groups, each group consists of 5 animals. Inflammation was induced by intra planter injection of histamine (0.1 mL of 1% histamine for induction of paw edema). The rats are challenged by s.c injection of 0.1 mL of 1% solution of histamine into the sub-plantar side of the left hind paw. 1 h after the administration of the test compounds (10 mg/kg; p.o), one group was kept as control, received only 0.5% carboxy methyl cellulose solution. The volume was measured before and after 3 h of carrageen treatment by means of plethysmometer.

The percentage of anti-inflammatory activity was calculated by = (Vc − Vt/Vc) × 100.Vc = control, Vt = test sample.

### 2.2.2. In vitro antibacterial screening {#s0060}

The antibacterial screening for isolated compounds was determined by the disc diffusion method ([@b0015]) using Mueller--Hinton agar (Hi-Media) medium. The synthesized compounds were evaluated against gram negative bacteria of *Escherichia coli* (MTCC-739), *Pseudomonas aeruginosa* (MTCC-2435), *Klebsiella pneumonia* (recultured) and gram positive bacteria of *Streptococcus epidermidis*, *Staphylococcus aureus* (MTCC-96). Synthesized compounds were initially screened by maximum concentration at 100 μg/mL in DMSO. The zone of inhibition was measured after 24 h incubation at 37 °C. The MIC was identified by twofold dilutions of the solution method (64, 32...., 0.5 μg/mL).

### 2.2.3. In vitro antifungal screening {#s0065}

The antifungal screening for isolated compounds was determined by using the disc diffusion method ([@b0120]) with Sabouraud's dextrose agar (Hi-Media). The isolated compounds were estimated for their in vitro antifungal activity against *Aspergillus niger*, *Candia albicans*, *Microsporum audouinii* and *Cryptococcus neoformans* (recultured). Synthesized compounds were initially screened by maximum concentration at 100 μg/mL in DMSO. The zone of inhibition (mm) was measured after incubation at 37 °C. The MIC was identified by twofold dilutions of the solution method (64, 32...., 0.5 μg/mL).

3. Results {#s0070}
==========

3.1. Synthesis and characterization of pyrazole analogues {#s0075}
---------------------------------------------------------

Title compounds (**1**--**6**) were synthesized from 5(3)-hydroxy-3(5)-methyl-1*H*-pyrazoles reacting with aldehyde and semicarbazide via Ultrasound irradiation under aqueous medium and without catalysis condition, the synthetic route of pyrazole derivatives is represented in [Scheme 1](#f0030){ref-type="fig"}. The compounds (**1**--**6**) were manufactured by Mannich base condensation method and the mechanism of the work outlined in [Scheme 1](#f0030){ref-type="fig"}. Physicochemical data of the compounds (**1**--**6**) are given in [Table 1](#t0005){ref-type="table"}.

Isolated compounds were characterized by Infra red, Proton NMR, Carbon NMR spectrum, Mass spectra, and elemental analyses.

Compound **1** was confirmed by IR spectral analysis, which indicates the value of 3445 cm^−1^ corresponding to the OH group nearby in the pyrazole ring and another absorption band at 670 cm^−1^ corresponding to the --CH-- group presented in the pyrazole ring. Another analysis of ^1^H NMR spectrum shows the signals observed at δ 13.03, 11.43, 5.45, 2.36, and 6.25 corresponding to NH in the pyrazole ring, C--OH, --CH--, NH, CH, and NH~2~ protons respectively and ^13^C NMR spectrum shows that peaks at δ 132.2, 51.2, and 12.7 correspond to C--OH, C--CH--NH, and CH~3~ carbons respectively. Molecular mass of compound **1** was confirmed by mass spectral analysis, which is indicated that the molecular ion peaks at 261.27(M^+^, 32%).

3.2. Anti-inflammatory activity {#s0080}
-------------------------------

Isolated products (**1**--**6**) were evaluated for anti-inflammatory activity match up with diclofenac sodium at oral dose. Rat albino was used as an oral dose of the test compound at a concentration of 10 mg/kg, the percentage of the activity was measured at 3 h. Compound (**4**) is highly active compared with standard. [Fig. 2](#f0010){ref-type="fig"} shows the activity difference of compounds (**1**--**6**), anti-inflammatory activity records are presented in [Table 2](#t0010){ref-type="table"}.

3.3. Antibacterial activity {#s0085}
---------------------------

Compound (**3**) is exceedingly active (MIC: 0.25 μg/mL) against gram negative bacteria of *E. coli* compared with Ciprofloxacin MIC: 0.5 μg/mL. Compound (**4**) (MIC: 0.25 μg/mL) is highly active and match up with standard (MIC: 4 μg/mL) against gram-negative bacteria of *S. epidermidis*. The bacterial zones of inhibition values are presented in [Table 3](#t0015){ref-type="table"} and [Fig. 3](#f0015){ref-type="fig"} indicates differentiation of antibacterial activity in isolated compounds (**1**--**6**).

3.4. Antifungal activity {#s0090}
------------------------

Compound (**2**) MIC: 1 μg/mL is greatly active against *A. niger* match up to with Clotrimazole MIC: 2 μg/mL. Compound (**3**) (MIC: 0.5 μg/mL) has equipotent activity against *M. audouinii* match up to with standard Clotrimazole (MIC: 0.5 μg/mL) whereas compound **5** (MIC: 4 μg/mL) is moderately active against *A. niger*. The fungal zones of inhibition values are presented in [Table 4](#t0020){ref-type="table"}. [Fig. 4](#f0020){ref-type="fig"} indicates differentiation of antifungal activity in isolated compounds of compounds (**1**--**6**). Minimal inhibitory concentration (MIC) data are reported in [Table 5](#t0025){ref-type="table"}.

4. Discussion {#s0095}
=============

The anti-inflammatory and antimicrobial performances of the isolated compounds were confirmed by structure--activity relationships ([Fig. 5](#f0025){ref-type="fig"}).

The 4-substituted phenyl ring with semicarbazone acts as a lipophilic and hydrogen bonding domain. Therefore, the above group containing the pyrazole ring may be stated as the essential pharmacophoric requirement for anti-inflammatory activity.

\(i\) Compound **3** (MIC: 0.25 μg/mL) pyrazole derivative exhibited high activity against gram negative *E. coli* compared with standard Ciprofloxacin and also antifungal activity of compound **3** exhibited equipotent activity (MIC: 0.5 μg/mL) against *M. audouinii* match up to with standard Clotrimazole (MIC: 0.5 μg/mL), reason of activity due to the presence of 4-OH-phenyl with semicarbazone and pyrazole moiety in compound **3**. (ii) Compound **2** (MIC: 1 μg/mL) is highly active against gram negative bacteria of *K. pneumoniae* and also highly active (MIC: 1 μg/mL) against *A. niger* compared with standard Clotrimazole (MIC: 2 μg/mL) in antifungal screening, 4-Cl-phenyl with semicarbazone and pyrazole moiety were represented to be highly active against *K. pneumoniae* bacterial and *A. niger* fungal strain. (iii) Compound **4** is highly active (MIC: 2 μg/mL) against gram positive bacteria of *S. epidermidis* compared with standard Ciprofloxacin (MIC: 4 μg/mL), reason of activity due to the presence of 4-NO~2~-phenyl with semicarbazone and pyrazole moiety in compound **4**. The compound **4** is very much active (82%) against anti-inflammatory in relation to Diclofenac sodium 74.0% of activity.

5. Conclusion {#s0100}
=============

In conclusion, synthesized compounds (**1**--**6**) were tested with anti-inflammatory and antimicrobial screening. Among the series, compound (**3**) (MIC : 0.25 μg/mL) was found to be the most active against gram negative bacterial strain *E. coli* compared with standard Ciprofloxacin, antifungal activity of compound (**2**) (MIC: 1 μg/mL) was greatly active against *A. niger* than standard Clotrimazole and compound (**4**) showed better activity against anti-inflammatory when compared with Diclofenac sodium. Therefore these derivatives could provide as a highly momentous molecule for further development of antimicrobial, anti-inflammatory agents.
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###### 

Physicochemical data of the compounds (**1**--**6**).

  Comp. No.   Ar              Yield %   mp°C   m.f                    m.w      Elemental analysis calculated (found)                 
  ----------- --------------- --------- ------ ---------------------- -------- --------------------------------------- ------------- ---------------
  **1**       --H             87        161    C~12~H~15~N~5~O~2~     261.27   55.16 (55.20)                           5.79 (5.71)   26.80 (26.79)
  **2**       --Cl            78        89     C~12~H~14~ClN~5~O~2~   295.72   44.74 (44.72)                           4.77 (4.76)   23.68 (23.65)
  **3**       --OH            81        121    C~12~H~15~N~5~O~3~     277.27   51.98 (51.97)                           5.45 (5.40)   25.26 (25.23)
  **4**       --NO~2~         72        134    C~12~H~14~N~6~O~4~     306.27   47.06 (47.10)                           4.61 (4.59)   27.44 (27.43)
  **5**       --OCH~3~        81        110    C~13~H~17~N~5~O~3~     291.30   53.60 (53.65)                           5.88 (5.86)   24.04 (24.08)
  **6**       --N(CH~3~)~2~   85        97     C~14~H~20~N~6~O~2~     304.34   55.25 (55.30)                           6.62 (6.60)   27.61 (27.60)

###### 

Anti-inflammatory activity of compounds (**1**--**6**).

  Comp. No   Increase in paw volume (3hr -- 0hr)   Percentage (%) of Activity, Dose (10 mg/ kg)
  ---------- ------------------------------------- ----------------------------------------------
  Control    0.56                                  --
  **1**      0.22 ± 0.05                           66.0^∗^
  **2**      0.18 ± 0.06                           67.8^∗^
  **3**      0.32 ± 0.06                           42.8^∗^
  **4**      0.10 ± 0.02                           82.1^∗^
  **5**      0.38 ± 0.09                           32.1^∗^
  **6**      0.41 ± 0.02                           26.7^∗^
  Standard   0.14 ± 0.01                           75.0^∗^

Mean ± SEM, *n* = 6 in each group. Significance levels ^∗^*P* \< 0.01 as compared with the respective control. Diclofenac sodium was used as a standard.

###### 

Antibacterial activity of isolated products (**1**--**6**).

  Compounds   Gram-negative   Gram-positive             
  ----------- --------------- --------------- ---- ---- ----
  **1**       12              --              --   --   12
  **2**       16              --              18   --   16
  **3**       28              8               --   10   10
  **4**       20              --              8    12   18
  **5**       18              12              10   \-   12
  **6**       15              --              --   14   14
  Standard    26              17              19   22   15

Ciprofloxacin used as a standard, zone of inhibition measured at (mm).

###### 

Antifungal activity of isolated products (**1**--**6**).

  Compounds   *A. niger*   *C. albicans*   *C. neoformans*   *M. audouinii*
  ----------- ------------ --------------- ----------------- ----------------
  **1**       10           --              --                12
  **2**       24           12              --                18
  **3**       15           16              8                 25
  **4**       14           10              --                10
  **5**       20           12              10                12
  **6**       18           --              --                10
  Standard    22           24              25                26

Clotrimazole used as a standard, zone of inhibition measured at (mm).

###### 

Minimum inhibition concentration of isolated products (**2**, **3** and **5**).

  Comp. No.       *E. c*   *P. a*   *K. p*   *S. a*   *S. e*   *A. n*   *C. a*   *C. n*   *M. a*
  --------------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  **2**           64       \>100    1        \>100    16       1        64       \>100    16
  **3**           0.25     64       \>100    64       64       64       64       \>100    0.5
  **4**           16       \>100    \>100    64       2        64       \>100    \>100    \>100
  **5**           16       32       64       \>100    16       4        64       64       32
  Ciprofloxacin   0.5      1        2        0.5      4        --       --       --       --
  Clotrimazole    --       --       --       --       --       2        1        0.5      0.5
